Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H13ClN2.ClH |
| Molecular Weight | 293.191 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=NC2=CC=CC=C2N1CC3=CC=C(Cl)C=C3
InChI
InChIKey=MHMTXDMLQZHXRZ-UHFFFAOYSA-N
InChI=1S/C15H13ClN2.ClH/c1-11-17-14-4-2-3-5-15(14)18(11)10-12-6-8-13(16)9-7-12;/h2-9H,10H2,1H3;1H
| Molecular Formula | C15H13ClN2 |
| Molecular Weight | 256.73 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chlormidazole was the first azole introduced the treatment of topical mycosis. It demonstrated inhibitory activity against many fungi and some gram-positive cocci. It is used for the treatment of fungal and bacterial infections of nails and skin, including interdigital and periungual mycoses. Possible side effects are: local skin irritation, burning, itching.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Clinical results in treatment of dermatomycoses with Myco-Polycid]. | 1973 Dec |
|
| [Efficacy of the Myco-Polycid preparation in the form of tincture and cream for the treatment of dermatomycoses]. | 1975 Dec |
|
| [Treatment of dermatomycoses with Myco-Polycid]. | 1975 May |
|
| Topical pharmacology of imidazole antifungals. | 1976 |
|
| [Antibacterial and antifungal compounds. V. Synthesis and antimicrobial activity of N-(2-arylethylaminophenyl)-1H-pyrryl-1-amine and 1-(1H-pyrrol-1-yl)-2-arylmethylbenzimidazole)]. | 1985 Jul |
|
| [Sensitivity of aerobic bacteria and Candida species to chlormidazole hydrochloride in vitro]. | 1990 Jan 22-29 |
|
| Azole antimycotics--a highway to new drugs or a dead end? | 2012 |
Patents
Sample Use Guides
2-3 times per day; Treatment should be continued for at least 4 weeks after complete elimination of discomfort.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:48:20 GMT 2023
by
admin
on
Fri Dec 15 18:48:20 GMT 2023
|
| Record UNII |
0RH29TB951
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000080073
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
53015
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
277-804-5
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
74298-63-8
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
SUB13329MIG
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
0RH29TB951
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | |||
|
m3377
Created by
admin on Fri Dec 15 18:48:20 GMT 2023 , Edited by admin on Fri Dec 15 18:48:20 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |